A comprehensive review on metabolic syndrome

Jaspinder Kaur, Jaspinder Kaur

Abstract

Metabolic syndrome is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Insulin resistance, visceral adiposity, atherogenic dyslipidemia, endothelial dysfunction, genetic susceptibility, elevated blood pressure, hypercoagulable state, and chronic stress are the several factors which constitute the syndrome. Chronic inflammation is known to be associated with visceral obesity and insulin resistance which is characterized by production of abnormal adipocytokines such as tumor necrosis factor α , interleukin-1 (IL-1), IL-6, leptin, and adiponectin. The interaction between components of the clinical phenotype of the syndrome with its biological phenotype (insulin resistance, dyslipidemia, etc.) contributes to the development of a proinflammatory state and further a chronic, subclinical vascular inflammation which modulates and results in atherosclerotic processes. Lifestyle modification remains the initial intervention of choice for such population. Modern lifestyle modification therapy combines specific recommendations on diet and exercise with behavioural strategies. Pharmacological treatment should be considered for those whose risk factors are not adequately reduced with lifestyle changes. This review provides summary of literature related to the syndrome's definition, epidemiology, underlying pathogenesis, and treatment approaches of each of the risk factors comprising metabolic syndrome.

Figures

Figure 1
Figure 1
Schematic presentation of MetS. (FFA: free fatty acid, ATII: angiotensin II, PAI-1: plasminogen activator inhibitor-1, RAAS: renin angiotensin aldosterone system, SNS: sympathetic nervous system.)

References

    1. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. 2009;120(16):1640–1645.
    1. Alberti KGMM, Zimmet P. The metabolic syndrome—a new worldwide definition. The Lancet. 2005;366(9491):1059–1062.
    1. Olijhoek JK, Van Der Graaf Y, Banga J-D, Algra A, Rabelink TJ, Visseren FLJ. The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. European Heart Journal. 2004;25(4):342–348.
    1. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. Journal of the American College of Cardiology. 2006;47(6):1093–1100.
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine. 1998;15(7):539–553.
    1. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR) Diabetic Medicine. 1999;16(5):442–443.
    1. Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) Journal of the American Medical Association. 2001;285(19):2486–2497.
    1. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocrine Practice. 2003;9(3):237–252.
    1. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome, .
    1. Shaw JE, Alberti KGMM. Point: impaired fasting glucose: the case for the new American Diabetes Association criterion. Diabetes Care. 2006;29(5):1170–1172.
    1. Shaw JE, Chisholm DJ. Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Medical Journal of Australia. 2003;179(7):379–383.
    1. Kylin E. Studien ueber das Hypertonie-Hyperglyca “mie- Hyperurika” miesyndrom. Zentralblatt fuer Innere Medizin. 1923;44:105–127.
    1. Vague J. Sexual differentiation. A factor affecting the forms of obesity. Presse Medicale. 1947;30:S39–S40.
    1. Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia. 1965;1:p. 137.
    1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.
    1. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Archives of Internal Medicine. 1989;149(7):1514–1520.
    1. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (Syndrome X) Diabetes. 1992;41(6):715–722.
    1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2005;365(9468):1415–1428.
    1. Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinology and Metabolism Clinics of North America. 2004;33(2):333–350.
    1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–2752.
    1. Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066–3072.
    1. Ritchie SA, Connell JMC. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutrition, Metabolism and Cardiovascular Diseases. 2007;17(4):319–326.
    1. Desroches S, Lamarche B. The evolving definitions and increasing prevalence of the metabolic syndrome. Applied Physiology, Nutrition and Metabolism. 2007;32(1):23–32.
    1. Kolovou GD, Anagnostopoulou KK, Salpea KD, Mikhailidis DP. The prevalence of metabolic syndrome in various populations. The American Journal of the Medical Sciences. 2007;333(6):362–371.
    1. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics of North America. 2004;33(2):351–375.
    1. Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Archives of Internal Medicine. 2003;163(4):427–436.
    1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. Journal of the American Medical Association. 2002;287(3):356–359.
    1. Ponholzer A, Temml C, Rauchenwald M, Marszalek M, Madersbacher S. Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women? International Journal of Impotence Research. 2008;20(1):100–104.
    1. Wilson PWF, Kannel WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Archives of Internal Medicine. 1999;159(10):1104–1109.
    1. Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident metabolic syndrome in adults: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27(3):788–793.
    1. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003;108(13):1546–1551.
    1. Andreadis EA, Tsourous GI, Tzavara CK, et al. Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population. The American Journal of Hypertension. 2007;20(5):558–564.
    1. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinology and Metabolism Clinics of North America. 2008;37(3):753–768.
    1. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. Journal of Lipid Research. 2005;46(11):2347–2355.
    1. Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. The American Journal of Physiology—Heart and Circulatory Physiology. 2005;288(5):H2031–H2041.
    1. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition. 2004;92(3):347–355.
    1. Saleem U, Khaleghi M, Morgenthaler NG, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. Journal of Clinical Endocrinology and Metabolism. 2009;94(7):2558–2564.
    1. Tsimikas S, Willeit J, Knoflach M, et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. European Heart Journal. 2009;30(1):107–115.
    1. Jacobs M, Van Greevenbroek MMJ, Van Der Kallen CJH, et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. European Journal of Clinical Investigation. 2009;39(6):437–444.
    1. Miles JM, Jensen MD. Counterpoint: visceral adiposity is not causally related to insulin resistance. Diabetes Care. 2005;28(9):2326–2328.
    1. Boden G, Lebed B, Schatz M, Homko C, Lemieux S. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes. 2001;50(7):1612–1617.
    1. Kahn SE, Prigeon RL, Schwartz RS, et al. Obesity, body fat distribution, insulin sensitivity and islet β-cell function as explanations for metabolic diversity. Journal of Nutrition. 2001;131(2):354S–360S.
    1. Xydakis AM, Case CC, Jones PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight lose through caloric restriction. Journal of Clinical Endocrinology and Metabolism. 2004;89(6):2697–2703.
    1. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science. 1996;271(5249):665–668.
    1. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496–1504.
    1. Soto González A, Bellido Guerrero D, Buño Soto M, Pértega Díaz S, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. European Journal of Clinical Nutrition. 2006;60(6):802–809.
    1. Deepa R, Velmurugan K, Arvind K, et al. Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES) Metabolism. 2006;55(9):1232–1238.
    1. Guldiken S, Demir M, Arikan E, et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thrombosis Research. 2007;119(1):79–84.
    1. McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106(23):2908–2912.
    1. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391–397.
    1. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. Journal of the American Osteopathic Association. 2005;105(9):409–416.
    1. Pedersen BK, Steensberg A, Fischer C, et al. Searching for the exercise factor: is IL-6 a candidate? Journal of Muscle Research and Cell Motility. 2003;24(2-3):113–119.
    1. Stenlöf K, Wernstedt I, Fjällman T, Wallenius V, Wallenius K, Jansson J-O. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. Journal of Clinical Endocrinology and Metabolism. 2003;88(9):4379–4383.
    1. Diamant M, Lamb HJ, Van De Ree MA, et al. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2005;90(3):1495–1501.
    1. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association. 2001;286(3):327–334.
    1. Zuliani G, Volpato S, Blè A, et al. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. Atherosclerosis. 2007;192(2):384–390.
    1. Alessi M-C, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(10):2200–2207.
    1. Cigolini M, Targher G, Andreis IAB, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16(3):368–374.
    1. Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Archives des Maladies du Coeur et des Vaisseaux. 2004;97(6):673–678.
    1. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. The New England Journal of Medicine. 2000;342(24):1792–1801.
    1. Liu M, Liu F. Transcriptional and post-translational regulation of adiponectin. Biochemical Journal. 2010;425(1):41–52.
    1. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24(1):29–33.
    1. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002;25(6):971–976.
    1. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. Journal of the American Medical Association. 2004;291(14):1730–1737.
    1. Fumeron F, Aubert R, Siddiq A, et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes. 2004;53(4):1150–1157.
    1. Lee H-S, Lee M, Joung H. Adiponectin represents an independent risk factor for hypertension in middle aged Korean women. Asia Pacific Journal of Clinical Nutrition. 2007;16(1):10–15.
    1. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50(9):2094–2099.
    1. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications. 2003;301(4):1045–1050.
    1. Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes. 2003;52(4):942–947.
    1. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation. 2000;102(11):1296–1301.
    1. Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. The American Journal of the Medical Sciences. 2005;330(6):280–289.
    1. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension. 2002;39(2):496–501.
    1. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension. 2003;41(5):1072–1079.
    1. Marsh AJ, Fontes MAP, Killinger S, Pawlak DB, Polson JW, Dampney RAL. Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus. Hypertension. 2003;42(4):488–493.
    1. Shirasaka T, Takasaki M, Kannan H. Cardiovascular effects of leptin and orexins. The American Journal of Physiology—Regulatory Integrative and Comparative Physiology. 2003;284(3):R639–R651.
    1. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. The New England Journal of Medicine. 1996;334(5):292–295.
    1. Bravata DM, Wells CK, Concato J, Kernan WN, Brass LM, Gulanski BI. Two measures of insulin sensitivity provided similar information in a U.S. population. Journal of Clinical Epidemiology. 2004;57(11):1214–1217.
    1. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45(5):633–638.
    1. Mayer-Davis EJ, D’Agostino R, Jr., Karter AJ, et al. Intensity and amount of physical activity in relation to insulin sensitivity the Insulin Resistance Atherosclerosis Study. Journal of the American Medical Association. 1998;279(9):669–674.
    1. Vessby B, Uusitupa M, Hermansen K, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study. Diabetologia. 2001;44(3):312–319.
    1. Gill H, Mugo M, Whaley-Connell A, Stump C, Sowers JR. The key role of insulin resistance in the cardiometabolic syndrome. The American Journal of the Medical Sciences. 2005;330(6):290–294.
    1. Petersen KF, Shulman GI. Etiology of insulin resistance. The American Journal of Medicine. 2006;119(5):S10–S16.
    1. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. Journal of Clinical Investigation. 1989;83(4):1168–1173.
    1. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans: implications for the insulin-resistant state. Diabetes Care. 1996;19(4):390–393.
    1. Ginsberg HN, Zhang Y-L, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Archives of Medical Research. 2005;36(3):232–240.
    1. Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. The American Heart Journal. 1991;121(4):1274–1282.
    1. Malhotra A, Kang BPS, Cheung S, Opawumi D, Meggs LG. Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes. 2001;50(8):1918–1926.
    1. Morse SA, Zhang R, Thakur V, Reisin E. Hypertension and the metabolic syndrome. The American Journal of the Medical Sciences. 2005;330(6):303–310.
    1. Briones AM, Cat AND, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59(5):1069–1078.
    1. Ordovas JM. Genetic links between diabetes mellitus and coronary atherosclerosis. Current Atherosclerosis Reports. 2007;9(3):204–210.
    1. Perseghin G, Ghosh S, Gerow K, Shulman GI. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes. 1997;46(6):1001–1009.
    1. Abate N, Chandalia M, Snell PG, Grundy SM. Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. Journal of Clinical Endocrinology and Metabolism. 2004;89(6):2750–2755.
    1. Martin LJ, North KE, Dyer T, Blangero J, Comuzzie AG, Williams J. Phenotypic, genetic, and genome-wide structure in the metabolic syndrome. BMC Genetics. 2003;4(supplement 1, article S95)
    1. Laakso M. Gene variants, insulin resistance, and dyslipidaemia. Current Opinion in Lipidology. 2004;15(2):115–120.
    1. Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A. Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes. 2005;54(1):275–283.
    1. Neel JV. Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? The American Journal of Human Genetics. 1962;14:353–362.
    1. Hales CN, Barker DJP. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992;35(7):595–601.
    1. Hales CN, Desai M, Ozanne SE. The thrifty phenotype hypothesis: how does it look after 5 years? Diabetic Medicine. 1997;14(3):189–195.
    1. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. Journal of the American Society of Nephrology. 2006;17(4, supplement 2):S81–S85.
    1. Bruce KD, Byrne CD. The metabolic syndrome: common origins of a multifactorial disorder. Postgraduate Medical Journal. 2009;85(1009):614–621.
    1. Padhi T, Garima Metabolic syndrome and skin: psoriasis and beyond. Indian Journal of Dermatology. 2013;58(3):299–305.
    1. Chopra R, Chander A, Jacob JJ. Ocular associations of metabolic syndrome. Indian Journal of Endocrinology and Metabolism. 2012;16(supplement 1):S6–S11.
    1. Lam JCM, Mary SMI. Sleep & the metabolic syndrome. Indian Journal of Medical Research. 2010;131(2):206–216.
    1. Dokras A, Bochner M, Hollinrake E, Markham S, Van Voorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstetrics and Gynecology. 2005;106(1):131–137.
    1. Standl E. Aetiology and consequences of the metabolic syndrome. European Heart Journal, Supplement. 2005;7(supplement D):D10–D13.
    1. Handelsman Y. Metabolic syndrome pathophysiology and clinical presentation. Toxicologic Pathology. 2009;37(1):18–20.
    1. Kraemer-Aguiar LG, Laflor CM, Bouskela E. Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome. Metabolism. 2008;57(12):1740–1746.
    1. Hansson GK. Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine. 2005;352(16):1685–1695.
    1. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. Journal of Clinical Investigation. 1997;100(9):2153–2157.
    1. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. Journal of Clinical Endocrinology and Metabolism. 2004;89(6):2595–2600.
    1. Aljada A, Mohanty P, Ghanim H, et al. Increase in intranuclear nuclear factor κB and decrease in inhibitor κB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. The American Journal of Clinical Nutrition. 2004;79(4):682–690.
    1. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448–1454.
    1. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annual Review of Physiology. 2005;67:259–284.
    1. Wang C-N, McLeod RS, Yao Z, Brindley DN. Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15(9):1481–1491.
    1. Argaud D, Zhang Q, Pan W, Maitra S, Pilkis SJ, Lange AJ. Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5′-flanking sequence. Diabetes. 1996;45(11):1563–1571.
    1. Hauner H, Entenmann G, Wabitsch M, et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. Journal of Clinical Investigation. 1989;84(5):1663–1670.
    1. Grunfeld C, Jones DS. Glucocorticoid-induced insulin resistance in vitro: inhibition of insulin-stimulated methylaminoisobutyric acid uptake. Hormone and Metabolic Research. 1986;18(3):149–152.
    1. Guillaume-Gentil C, Assimacopoulos-Jeannet F, Jeanrenaud B. Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia. 1993;36(10):899–906.
    1. Andrew R, Gale CR, Walker BR, Seckl JR, Martyn CN. Glucocorticoid metabolism and the metabolic syndrome: associations in an elderly cohort. Experimental and Clinical Endocrinology and Diabetes. 2002;110(6):284–290.
    1. Chrousos GP. Stress and disorders of the stress system. Nature Reviews Endocrinology. 2009;5(7):374–381.
    1. Wong ND. Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. Preventive Cardiology. 2005;8(1):47–54.
    1. Deen D. Metabolic syndrome: time for action. The American Family Physician. 2004;69(12):2875–2887.
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel III) final report. Circulation. 2002;106(25):3143–3421.
    1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. Journal of the American Medical Association. 2003;289(19):2560–2572.
    1. American Diabetes Association. Clinical practice recommendations 2005. Diabetes Care. 2005;28(supplement 1):S1–79.
    1. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report. National Institutes of Health. Obesity Research. 1998;6(supplement 2):51S–209S.
    1. Bellentani S, Grave RD, Suppini A, et al. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008;47(2):746–754.
    1. Donato KA. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Archives of Internal Medicine. 1998;158(17):1855–1867.
    1. Duncan GE, Perri MG, Theriaque DW, Hutson AD, Eckel RH, Stacpoole PW. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care. 2003;26(3):557–562.
    1. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. International Journal of Obesity. 1997;21(supplement 1):S5–S9.
    1. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. Journal of the American Medical Association. 1998;279(11):839–846.
    1. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Archives of Internal Medicine. 1987;147(10):1749–1753.
    1. Ross R, Janssen I, Dawson J, et al. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obesity Research. 2004;12(5):789–798.
    1. Hill JO, Wyatt HR. Role of physical activity in preventing and treating obesity. Journal of Applied Physiology. 2005;99(2):765–770.
    1. Haslam DW, James WPT. Obesity. The Lancet. 2005;366(9492):1197–1209.
    1. Toumilheto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus with lifestyle intervention or metformin. The New England Journal of Medicine. 2001;344(18):1343–1350.
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine. 2002;346(6):393–403.
    1. Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, Basterra-Gortari FJ, Nũnez-Cordoba JM, Martinez-Gonzalez MA. Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. Diabetes Care. 2007;30(11):2957–2959.
    1. Landaeta-Diaz L, Fernandez JM, Da Silva-Grigoletto M, et al. Mediterranean diet, moderate-to-high intensity training, and health-related quality of life in adults with metabolic syndrome. European Journal of Preventive Cardiology. 2013;20(4):555–564.
    1. Paletas K, Athanasiadou E, Sarigianni M, et al. The protective role of the mediterranean diet on the prevalence of metabolic syndrome in a population of greek obese subjects. Journal of the American College of Nutrition. 2010;29(1):41–45.
    1. Babio N, Bulló M, Basora J, et al. Adherence to the Mediterranean diet and risk of metabolic syndrome and its components. Nutrition, Metabolism and Cardiovascular Diseases. 2009;19(8):563–570.
    1. Lien LF, Brown AJ, Ard JD, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007;50(4):609–616.
    1. Garg A, Bantle JP, Henry RR, et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. Journal of the American Medical Association. 1994;271(18):1421–1428.
    1. Mitch WE. Beneficial responses to modified diets in treating patients with chronic kidney disease. Kidney International, Supplement. 2005;67(94):S133–S135.
    1. Fabricatore AN. Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference? Journal of the American Dietetic Association. 2007;107(1):92–99.
    1. Wing RR, Jeffery RW, Burton LR, Thorson C, Nissinoff KS, Baxter JE. Food provision vs structured meal plans in the behavioral treatment of obesity. International Journal of Obesity. 1996;20(1):56–62.
    1. Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. Obesity Research. 2004;12(S12):151S–162S.
    1. Johnson AG, Nguyen TV, Davis D. Blood pressure is linked to salt intake and modulated by the angiotensinogen gene in normotensive and hypertensive elderly subjects. Journal of Hypertension. 2001;19(6):1053–1060.
    1. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. Journal of the American Medical Association. 1999;282(21):2027–2034.
    1. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: first national health and nutrition examination survey epidemiologic follow-up study. Archives of Internal Medicine. 2002;162(14):1619–1624.
    1. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47(2):296–308.
    1. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. Journal of the American Medical Association. 1997;277(20):1624–1632.
    1. American Diabetes Association. Evidence based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2002;25(1):202–212.
    1. Jenkins DJA, Kendall CWC, Augustin LSA, et al. Glycemic index: overview of implications in health and disease. The American Journal of Clinical Nutrition. 2002;76(1):266S–273S.
    1. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PWF, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care. 2004;27(2):538–546.
    1. Thompson PD, Buchner D, Piña IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the council on clinical cardiology (subcommittee on exercise, rehabilitation, and prevention) and the council on nutrition, physical activity, and metabolism (subcommittee on physical activity) Circulation. 2003;107(24):3109–3116.
    1. Grundy SM, Hansen B, Smith SC, Jr., Cleeman JI, Kahn RA. American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109(4):551–556.
    1. Pollock ML, Franklin BA, Balady GJ, et al. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation. 2000;101(7):828–833.
    1. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165–2171.
    1. Haskell WL, Lee I-M, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116(9):1081–1093.
    1. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. Journal of Clinical Endocrinology and Metabolism. 2001;86(12):5755–5761.
    1. Slentz CA, Duscha BD, Johnson JL, et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE—a randomized controlled study. Archives of Internal Medicine. 2004;164(1):31–39.
    1. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. Journal of the American Medical Association. 1995;273(5):402–407.
    1. Ford ES, Kohl HW, III, Mokdad AH, Ajani UA. Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults. Obesity Research. 2005;13(3):608–614.
    1. Koplan JP, Dietz WH. Caloric imbalance and public health policy. Journal of the American Medical Association. 1999;282(16):1579–1581.
    1. Wing RR. Behavioral weight control. In: Wadden TA, Stunkard AJ, editors. Handbook of Obesity Treatment. New York, NY, USA: Guildford Press; 2002. pp. 301–316.
    1. Wadden TA, McGuckin BG, Rothman RA, Sargent SL. Lifestyle modification in the management of obesity. Journal of Gastrointestinal Surgery. 2003;7(4):452–463.
    1. Ferrari CKB. Functional foods and physical activities in health promotion of aging people. Maturitas. 2007;58(4):327–339.
    1. Wilson PWF, Grundy SM. The metabolic syndrome practical guide to origins and treatment: part I. Circulation. 2003;108(12):1422–1424.
    1. Krejs GJ. Metabolic benefits associated with sibutramine therapy. International Journal of Obesity. 2002;26(supplement 4):S34–S37.
    1. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25(7):1123–1128.
    1. Haddock CK, Poston WSC, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. International Journal of Obesity. 2002;26(2):262–273.
    1. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.
    1. Folli F, Pontiroli AE, Schwesinger WH. Metabolic aspects of bariatric surgery. Medical Clinics of North America. 2007;91(3):393–414.
    1. Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. The New England Journal of Medicine. 2004;351(26):2683–2693.
    1. Wolfe BM, Morton JM. Weighing in on bariatric surgery: procedure use, readmission rates, and mortality. Journal of the American Medical Association. 2005;294(15):1960–1963.
    1. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Journal of the American Medical Association. 1996;275(2):128–133.
    1. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association. 1998;279(20):1615–1622.
    1. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23):III39–III43.
    1. Bloomgarden ZT. Obesity, hypertension, and insulin resistance. Diabetes Care. 2002;25(11):2088–2097.
    1. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. The American Journal of Cardiology. 2005;95(3):360–366.
    1. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. The American Journal of Cardiology. 2002;89(6):672–678.
    1. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release Niacin on lipoprotein subclass distribution. The American Journal of Cardiology. 2003;91(12):1432–1436.
    1. Hunninghake DB, McGovern ME, Koren M, et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clinical Cardiology. 2003;26(3):112–118.
    1. Mills E, Prousky J, Raskin G, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTNI8054903] BMC Clinical Pharmacology. 2003;3, article 4
    1. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Archives of Internal Medicine. 2002;162(14):1568–1576.
    1. Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. Journal of the American Medical Association. 1989;262(22):3154–3160.
    1. Steiner G. Fibrates in the metabolic syndrome and in the diabetes. Endocrinology and Metabolism Clinics of North America. 2004;33(3):545–556.
    1. Streja D. Combination therapy for the treatment of dyslipidemia. Current Opinion in Investigational Drugs. 2004;5(3):306–312.
    1. Vega GL, Ma PTS, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. The American Journal of Cardiology. 2003;91(8):956–960.
    1. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Current Medical Research and Opinion. 2003;19(3):155–168.
    1. Turley SD, Dietschy JM. The intestinal absorption of biliary and dietary cholesterol as a drug target for lowering the plasma cholesterol level. Preventive Cardiology. 2003;6(1):29–64.
    1. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. The American Journal of Cardiology. 2002;90(10):1092–1097.
    1. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Current Medical Research and Opinion. 2007;23(8):2009–2026.
    1. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Journal of the American Medical Association. 1984;251(3):365–374.
    1. Engeli S, Böhnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356–362.
    1. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. Journal of the American Medical Association. 2002;288(15):1882–1888.
    1. Israili ZH, Lyoussi B, Hernández-Hernández R, Velasco M. Metabolic syndrome: treatment of hypertensive patients. The American Journal of Therapeutics. 2007;14(4):386–402.
    1. Ball SG, White WB. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers—a gap in evidence-based medicine. The American Journal of Cardiology. 2003;91(10):15G–21G.
    1. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. The New England Journal of Medicine. 2004;351(19):1952–1961.
    1. Abuissa H, Jones PG, Marso SP, O’Keefe JH., Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of the American College of Cardiology. 2005;46(5):821–826.
    1. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. The New England Journal of Medicine. 2006;355(15):1551–1562.
    1. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. Journal of Hypertension. 2006;24(1):3–10.
    1. Pasternak RC. The ALLHAT lipid lowering trial—less is less. Journal of the American Medical Association. 2002;288(23):3042–3044.
    1. Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) Diabetes Care. 2008;31(2):353–360.
    1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Journal of the American Medical Association. 2002;288(23):2981–2997.
    1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
    1. Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54(4):1150–1156.
    1. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The Lancet. 2002;359(9323):2072–2077.
    1. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial. Annals of Internal Medicine. 2005;142(8):611–619.
    1. Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28(4):888–894.
    1. Molitch ME. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003;26(4):977–980.
    1. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Journal of the American Medical Association. 2003;290(4):486–494.
    1. Rajagopalan R, Iyer S, Khan M. Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Current Medical Research and Opinion. 2005;21(1):163–172.
    1. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation. 2003;107(3):499–511.
    1. Schieffer B, Bünte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. Journal of the American College of Cardiology. 2004;44(2):362–368.
    1. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine. 2008;359(21):2195–2207.
    1. Shields TM, Hennekens CH. Management of metabolic syndrome: aspirin. Endocrinology and Metabolism Clinics of North America. 2004;33(3):577–593.
    1. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American heart association. Circulation. 1997;96(8):2751–2753.
    1. Blaha MJ, Bansal S, Rouf R, Golden SH, Blumenthal RS, DeFilippis AP. A practical “ABCDE” approach to the metabolic syndrome. Mayo Clinic Proceedings. 2008;83(8):932–943.
    1. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Archives of Internal Medicine. 2003;163(17):2006–2010.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere